Related Experiment Video
Updated: Aug 24, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
[Is cellular immunity not impaired after remission induction in acute lymphoblastic leukemia in children]
Włodzimierz Łuczyński1, Anna Stasiak-Barmuta, Maryna Krawczuk-Rybak
1Klinika Onkologii Dzieciecej Akademii Medycznej w Białymstoku. vlodek@amb.ac.bialystok.pl
Insights
Children with acute lymphoblastic leukemia (ALL) show lower lymphocyte counts at diagnosis. Treatment-induced immune suppression primarily affects immunoglobulin G production, necessitating monitoring and potential supplementation.
Area of Science:
- Pediatric Oncology
- Immunology
- Hematology
Background:
- Acute lymphoblastic leukemia (ALL) is a common childhood cancer.
- Understanding immune system changes during ALL treatment is crucial for patient management.
Purpose of the Study:
- To assess the immune system in children with ALL at diagnosis and after remission induction.
- To compare immune parameters between standard and high-risk ALL treatment protocols.
Main Methods:
- Studied 30 children with ALL, divided into standard (BFM protocol) and high-risk (New York protocol) groups.
- Measured infection episodes, leukocytosis, immunoglobulin levels (G, M, A, E), and lymphocyte subpopulations (CD19+, CD3+, CD4+, CD8+, etc.).
Main Results:
- At diagnosis, patients had higher leukocytosis and lower lymphocyte counts/subpopulations compared to controls.
- After remission induction, immunoglobulin G levels significantly decreased.
- Leukocytosis reduced, but CD19+ lymphocyte counts decreased, while CD3+ and CD8+ lymphocyte percentages increased post-treatment.
Conclusions:
- Children with ALL exhibit reduced lymphocyte counts at diagnosis.
- Immune suppression post-remission induction mainly impacts humoral immunity, specifically IgG production.
- Impaired humoral immunity in ALL is a treatment effect, not disease-related, warranting immune assessment and supplementation.
Unlabelled:
We examined immune system at the time of diagnosis and after remission induction in the group of 30 children (aged 6.5 +/- 3.6) with acute pre-B lymphoblastic leukaemia (ALL). The group was divided into standard risk group (treated with BFM protocol, n = 20) and high risk group (New York protocol, n = 10). We measured: episodes of infection, leukocytosis, immunoglobulin concentrations (G, M, A and E), lymphocytes and their subpopulations (CD19+, CD3+, CD3 + HLA-DR+, CD4+, CD8+, CD4 + CD45RA+, CD4 + CD45RO+, CD8 + CD45RA+, CD8 + CD45RO+, CD16 + CD56+).
Results:
Immunoglobulin concentrations at the time of diagnosis were normal, and decreased after remission induction only reduction of IgG concentration was statistically significant (p = 0.008). At the time of diagnosis we noted the following differences in examined group compared to control group: higher leukocytosis (p = 0.03), lower lymphocyte count (p = 0.0008), significantly lower lymphocyte subpopulation count (for subpopulations CD19+; CD3+; CD4+; CD8+ and CD16 + 56+). After remission induction comparing to the time of diagnosis we observed: total leukocytosis reduction (p = 0.01), percentage and count CD19+ lymphocytes reduction (adequately p = 0.000007, p = 0.03), increase of lymphocyte CD3+ percentage (p = 0.002) and CD8+ lymphocyte percentage (p = 0.00003).
Conclusions:
1. At the time of diagnosis of acute lymphoblastic leukaemia in children lower counts of all lymphocyte populations are observed. 2. Immune suppression after remission induction in this group of patients concerns mainly humoral response, particularly immunoglobulin G production. 3. Severe infections in patients treated for acute lymphoblastic leukaemia are indication to immunological system assessment and early immunoglobulin supplementations of deficits e.g. immunoglobulin infusions. 4. Humoral immunity impairment in children with ALL is an effect of treatment, not disease.
More Related Videos
06:32A Neonatal Intravenous Transplant Model for Assessment of Early-Life Immune Activities Against Cancer Cells
Published on: June 26, 2026
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Related Concept Videos
Cells of the Adaptive Immune Response
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Cell-mediated Immune Responses
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Immunological Memory
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature is...
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...